NAMS, NAMSW · CIK 0001936258 · operating
NewAmsterdam Pharma is a late-stage biopharmaceutical company developing therapies for cardiometabolic diseases. The company is headquartered in Naarden, the Netherlands, and operates with approximately 100 full-time employees. Its primary focus is on oral drug candidates targeting cardiovascular and metabolic conditions in patient populations with elevated cardiovascular risk.
The company's lead program is Obicetrapib, an oral CETP inhibitor designed to lower LDL cholesterol levels. Obicetrapib is being evaluated as both a standalone therapy and in combination with ezetimibe across multiple clinical trials for cardiovascular indications. Additionally, the company is developing Obicetrapib in a Phase 2a clinical trial for Alzheimer's disease, exploring potential neuroprotective benefits in neurodegenerative conditions.
The company generates revenue through its biopharmaceutical development activities. As a late-stage clinical entity, NewAmsterdam Pharma's business model centers on advancing its drug candidates through clinical development with the objective of obtaining regulatory approval and commercialization. The company maintains operations primarily in the Netherlands while pursuing a global development and commercialization strategy for its pipeline assets.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.72 | $-1.72 | +32.8% | |
| 2024 | $-2.56 | $-2.56 | -19.1% | |
| 2023 | $-2.15 | $-2.15 | — |